Published in

American Association for the Advancement of Science, Science, 6520(370), 2020

DOI: 10.1126/science.abd4250

Links

Tools

Export citation

Search in Google Scholar

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Journal article published in 2020 by Ellen Shrock, Richard T. Timms, Adam Zuiani, Meghan Travers, Alexandra-Chloé Villani, Xu G. Yu, Bruce D. Walker, Duane R. Wesemann, Jessica Tantivit, Molly Fisher Thomas, Elizabeth Suschana, Vivine Wilson, Xiaoming Sun, Hannah Ticheli, Alicja Trocha-Piechocka and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Profiling coronaviruses Among the coronaviruses that infect humans, four cause mild common colds, whereas three others, including the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), result in severe infections. Shrock et al. used a technology known as VirScan to probe the antibody repertoires of hundreds of coronavirus disease 2019 (COVID-19) patients and pre–COVID-19 era controls. They identified hundreds of antibody targets, including several antibody epitopes shared by the mild and severe coronaviruses and many specific to SARS-CoV-2. A machine-learning model accurately classified patients infected with SARS-CoV-2 and guided the design of an assay for rapid SARS-CoV-2 antibody detection. The study also looked at how the antibody response and viral exposure history differ in patients with diverging outcomes, which could inform the production of improved vaccine and antibody therapies. Science , this issue p. eabd4250